News

Acetyl-DL-leucine in two individuals with REM sleep behavior disorder improves symptoms, reverses loss of striatal dopamine-transporter binding and stabilizes pathological metabolic brain pattern—case reports | Nature Communications

Clinical 72/100How we got 72/100Source tierEstablished referenceTier ceiling72/100Independent sourcesnot recordedPublished score72/100Scored at the ceiling for a established reference source — it cannot go higher. The number is the source page’s own score, hard-capped at the tier ceiling; corroboration is recorded but cannot lift a score past that cap. Under 40 a claim goes to review instead of publication. Full methodology →
July 31, 2026↗ source

A case report published in Nature Communications suggests that the peptide derivative acetyl-DL-leucine (ADLL) may modify the progression of prodromal Parkinson's disease. In two patients with isolated REM sleep behavior disorder (iRBD), long-term treatment with ADLL not only reduced sleep symptoms but also appeared to reverse the loss of dopamine transporter binding in the brain. These findings indicate that ADLL could potentially slow or stabilize neurodegeneration associated with Parkinson's.

Related peptides

leucineSleep
We summarize, we don't invent — every detail here traces to a real, linked source, and the badge reflects how trustworthy that source is. Read the original and decide for yourself.